{"id":"W2955160320","doi":"10.1200/jco.2013.31.15_suppl.531","title":"Phase II randomized study of the EGFR, HER2, HER3 signaling inhibitor AZD8931 in combination with anastrozole (A) in women with endocrine therapy (ET) naive advanced breast cancer (MINT).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Jewish General Hospital","funders":"","keywords":"Medicine; Anastrozole; Internal medicine; Clinical endpoint; Breast cancer; Population; Interim analysis; Oncology; Placebo; Cancer; Gastroenterology; Randomized controlled trial; Tamoxifen; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002349871,0.0002400056,0.002374737,0.000211822,0.00004244501,0.000007832685,0.0002145242,0.000111571,0.0001578742],"category_scores_gemma":[0.0003156363,0.0001221248,0.0001561056,0.0004463576,0.0004041762,0.000344463,0.00005123259,0.001082729,6.12195e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005054233,"about_ca_system_score_gemma":0.001193258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004677495,"about_ca_topic_score_gemma":0.0005825081,"domain_scores_codex":[0.9954467,0.001154686,0.002272697,0.0002520902,0.0005349405,0.0003388678],"domain_scores_gemma":[0.9950032,0.001391728,0.002448135,0.000234991,0.0007408939,0.000181051],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5761476,0.02111083,0.05322717,0.00002425598,0.0006525181,0.0001440099,0.004796501,0.001654649,0.003540158,0.00001280099,0.00001338019,0.3386761],"study_design_scores_gemma":[0.77249,0.04898681,0.1680745,0.0006404564,0.0001065964,0.0002130234,0.007826984,0.0001067693,0.0007443997,0.0002281329,0.0004320997,0.0001502786],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901281,0.0003687606,0.00009713767,0.007181797,0.0002472537,0.001915232,0.00000326376,0.000007408026,0.00005106954],"genre_scores_gemma":[0.9967962,0.0002713354,0.001029303,0.001365606,0.000205838,0.0002507466,5.974216e-7,0.00003229989,0.00004809915],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3385259,"threshold_uncertainty_score":0.4980106,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03122237568613488,"score_gpt":0.4148741344509979,"score_spread":0.383651758764863,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}